Enovis Corporation

NYSE:ENOV Stock Report

Market Cap: US$1.9b

Enovis Valuation

Is ENOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ENOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$142.84
Fair Value
77.6% undervalued intrinsic discount
9
Number of Analysts

Below Fair Value: ENOV ($31.99) is trading below our estimate of fair value ($142.84)

Significantly Below Fair Value: ENOV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENOV?

Key metric: As ENOV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ENOV. This is calculated by dividing ENOV's market cap by their current revenue.
What is ENOV's PS Ratio?
PS Ratio0.8x
SalesUS$2.19b
Market CapUS$1.88b

Price to Sales Ratio vs Peers

How does ENOV's PS Ratio compare to its peers?

The above table shows the PS ratio for ENOV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.6x
ATRC AtriCure
3.5x11.42%US$1.8b
LMAT LeMaitre Vascular
8.6x8.60%US$2.0b
AORT Artivion
5.2x10.73%US$2.1b
CNMD CONMED
1.1x5.55%US$1.5b
ENOV Enovis
0.8x6.36%US$1.9b

Price-To-Sales vs Peers: ENOV is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (4.6x).

Price to Sales Ratio vs Industry

How does ENOV's PS Ratio compare vs other companies in the US Medical Equipment Industry?

59 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.8x8.4%
ENOV Enovis
 0.8x6.36%US$1.88b
XRAY DENTSPLY SIRONA
0.7x2.22%US$2.61b
QDEL QuidelOrtho
0.7x2.53%US$1.91b
ENOV 0.8xIndustry Avg. 2.8xNo. of Companies59PS03.67.210.814.418+
59 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.8x13.4%
ENOV Enovis
 0.8x118.00%US$1.88b
No more companies

Price-To-Sales vs Industry: ENOV is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Medical Equipment industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is ENOV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENOV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: ENOV is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ENOV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$31.99
US$49.67
+55.26%
17.03%US$60.00US$33.00n/a9
Oct ’26US$30.46
US$49.67
+63.06%
17.03%US$60.00US$33.00n/a9
Sep ’26US$30.90
US$52.20
+68.93%
21.17%US$75.00US$33.00n/a10
Aug ’26US$25.74
US$56.30
+118.73%
19.59%US$75.00US$37.00n/a10
Jul ’26US$33.02
US$56.50
+71.11%
19.21%US$75.00US$37.00n/a10
Jun ’26US$31.30
US$56.50
+80.51%
19.21%US$75.00US$37.00n/a10
May ’26US$34.60
US$64.20
+85.55%
14.29%US$75.00US$46.00n/a10
Apr ’26US$37.18
US$64.50
+73.48%
13.82%US$75.00US$46.00n/a10
Mar ’26US$38.65
US$65.00
+68.18%
14.37%US$75.00US$46.00n/a10
Feb ’26US$46.98
US$66.00
+40.49%
12.44%US$75.00US$50.00n/a10
Jan ’26US$43.88
US$66.00
+50.41%
12.44%US$75.00US$50.00n/a10
Dec ’25US$48.81
US$66.30
+35.83%
12.18%US$75.00US$50.00n/a10
Nov ’25US$42.43
US$66.50
+56.73%
12.24%US$75.00US$50.00n/a10
Oct ’25US$41.47
US$67.00
+61.56%
12.59%US$75.00US$50.00US$30.469
Sep ’25US$46.60
US$68.30
+46.57%
11.79%US$76.00US$50.00US$30.9010
Aug ’25US$46.54
US$72.10
+54.92%
12.26%US$82.00US$53.00US$25.7410
Jul ’25US$44.35
US$72.18
+62.75%
11.31%US$82.00US$53.00US$33.0211
Jun ’25US$50.27
US$74.10
+47.40%
7.74%US$82.00US$64.00US$31.3010
May ’25US$55.40
US$75.20
+35.74%
6.00%US$82.00US$65.00US$34.6010
Apr ’25US$61.43
US$75.20
+22.42%
6.00%US$82.00US$65.00US$37.1810
Mar ’25US$60.38
US$75.20
+24.54%
6.00%US$82.00US$65.00US$38.6510
Feb ’25US$59.61
US$71.33
+19.67%
5.91%US$75.00US$63.00US$46.989
Jan ’25US$56.02
US$69.25
+23.62%
7.87%US$75.00US$60.00US$43.888
Dec ’24US$50.97
US$67.57
+32.57%
8.94%US$75.00US$60.00US$48.817
Nov ’24US$45.03
US$70.00
+55.45%
5.07%US$75.00US$65.00US$42.437
Oct ’24US$52.73
US$69.83
+32.44%
4.63%US$75.00US$65.00US$41.476
US$49.67
Fair Value
35.6% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/29 04:39
End of Day Share Price 2025/10/29 00:00
Earnings2025/07/04
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enovis Corporation is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Robert CornellBarclays
Andrew ObinBofA Global Research